BLOCK HF trial
This article was originally published in The Gray Sheet
Executive Summary
Ability of Medtronic's InSync III cardiac resynchronization device to slow the progress of NYHA Class I, II and III heart failure with bi-ventricular pacing will be assessed in the 1,200-patient, 65-center trial. The first U.S. implant was announced Jan. 22. BLOCK HF is similar to Guidant's recently launched MADIT-CRT trial, which will evaluate the Contak Renewal 3 ICD's ability to retard HF progression (1"The Gray Sheet" Nov. 10, 2003, p. 42)...